An interventional study of Deep active rTMS with Hesed coil and Sham rTMS with Hesed coil in Neuropathic Pain and Fibromyalgia, sponsored by Nadine ATTAL. Recruiting at 2 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Nadine ATTAL · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Neuralgia with a site in France — 39 open to participants now, 40 under way, 4 of them phase 3. Neuralgia · France.
Among the 132 studies in Neuralgia with a site in France, this one is the 42nd largest by planned enrollment of the 102 interventional ones that give a count, is one of 10 that started in 2024, is one of 46 with no phase, reaches primary completion later than 11 of the 39 other live ones, and was the 108th registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →39 of the 132 studies in Neuralgia with a site in France are open now. Recruiting first, the newest first:
Hospital Ambroise Paré Paris · Sites in France
Ages 18–80
Hopitaux de Saint-Maurice · Sites in France
Ages 5–18
Poitiers University Hospital · Sites in France
Ages 18–80
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18–85
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 34 · Phase 3 15 · Phase 4 7
First in 2001; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 52 across 833 interventional studies indexed under Neuralgia.
Median enrollment 62 across the 102 interventional studies, 81 across the 30 observational. Of the 82 that completed or were terminated, 8 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 132 have an industry lead sponsor. The 10 most frequent:
Nadine ATTAL is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Nadine ATTAL has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
14 of the studies in Neuralgia with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06023706Phase 3Nantes University HospitalStudy Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia. | 2027-05-08 |
| NCT04867187Centre Hospitalier Universitaire de Saint EtiennerTMS Efficacy Coupled With Mirror Therapy | 2026-12 |
| NCT06964243Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy)Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain | 2026-12-19 |
| NCT06250491Nadine ATTALDeep rTMS (H-coil) for Neuropathic Pain or Fibromyalgia | 2027-01-30 |
| NCT06796595UBOSGAPerioperative Medical Program to Optimize Nerve Regeneration After Robot-assisted Laparoscopic Neurolyses of Pudendal and/or Inferior Cluneal Nerves for Chronic Neuralgias: Results After 1-year Follow-up | 2027-01-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 132 studies in Neuralgia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will investigate the efficacy and safety of "deep" rTMS on neuropathic pain or fibromyalgia. It will be randomized and sham controlled and will last 3 months. Patients will be randomized to receive acctive rTMS or sham rTMS and will receive repeated rTMS sessions (5 daily sessions then one session per week then every 2 to 3 weeks for up to 10 weeks).
This double blind sham controlled parallel group bicenter study will assess the efficacy and safety of repeated sessions of deep rTMS using H coil in patients with neuropathic pain or fibromyalgia. Primary outcome will be % of pain relief at week 13.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Deep rTMS with H coil targeting the motor cortex bilaterally
Device: Deep active rTMS with Hesed coil · Device: Sham rTMS with Hesed coil
Sham rTMS with H coil targeting the motor cortex bilaterally
Device: Deep active rTMS with Hesed coil · Device: Sham rTMS with Hesed coil
This brain neurostimulation method targets the motor cortex bilaterally
This brain sham neurostimulation method targets the motor cortex bilaterally
Effects of rTMS versus sham rTMS on pain relief at 13 weeks
Pain relief scale from the Brief Pain Inventory rated from 0 to 100 %
Time frame: 13 weeks
Effects of rTMS vs sham on average pain intensity
Average pain intensity from the Brief Pain Inventory rated from 0 to 10 on a 0-10 numerical pain scale
Time frame: Each follow up visit at the pain center for up to 13 weeks
Effects of rTMS vs sham on pain interference
pain interference from Brief Pain Inventory rated from 0 to 70 (total score)
Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks
Effects of rTMS vs sham on quality of life
Euroqol scale which includes 5 dimensions of quality of life and a 0-100 visual analog scale
Time frame: Baseline then each follow up vist at the pain center for up to 13 weeks
Side effects of rTMS or sham
Any side effects reported by the patients assessed at each visit after each treatment session and rated as mild, moderate or severe
Time frame: Each follow up visit at the pain center for up to 13 weeks
Comparison of the efficacy of rTMS on the primary outcome between patients with neuropathic pain and fibromyalgia
Comparison of both populations on the pain relief scale from the Brief Pain Inventory (0-100 %)
Time frame: Week 13
Blinding assessment
Blindinq questionnaire at 13 weeks(end of the study)
Time frame: 13 weeks
Patient global impression of change
Patient global impression of change at 13 weeks (from much improved to much deteriorated)
Time frame: 13 weeks
Self-reported pain intensity
Average pain intensity from past 24 hours based on 0-10 numerical pain scale
Time frame: Baseline then every day at the same time of day (morning or evening)
Effects of rTMS versus sham on anxiety and depressive symptoms
Anxiety and depressive symptoms of the Hospital Anxiety and Depressive scale rated from 0 to 21 for anxiety and 0 to 21 for depression
Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks
Effects of rTMS vs sham on pain as its worst from Brief Pain Inventory
pain intensity on 0-10 numerical rating scale
Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks
Effects of rTMS vs sham on pain as its least from Brief Pain Inventory
pain intensiy on 0-10 numerical rating scale
Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks
Effects of rTMS vs sham on sleep
Sleep assessed using the sleep scale from the Medical Outcome Survey
Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks
Effects of rTMS vs sham on pain right now from Brief Pain Inventory
pain intensiy on 0-10 numerical rating scale
Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks
Effects on Global Impression of change assessed by the clinician
Clinician global impression of change (from much improved to much deteriorated)
Time frame: 13 weeks (end of the treatment)
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.
Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 36 months is above that.
Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nadine ATTAL